| 臺大學術典藏 |
2021-09-01T01:53:48Z |
Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
|
Ou D.-L.; Lee B.-S.; Chang Y.-C.; Lin L.-I.; Liou J.-Y.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:25Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:24Z |
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin
|
Ou D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:18Z |
Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Ou D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:43Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; ANN-LII CHENG; Ou D.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-11T03:46:42Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:38Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2021-05-02T03:56:41Z |
Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer
|
Ou D.-L.; Tseng S.-J.; Kempson I.M.; Hsu C.-L.; PAN-CHYR YANG; Liao Z.-X. |
| 臺大學術典藏 |
2021-03-15T07:59:42Z |
MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine
|
Lu J.-W.;Lin Y.-M.;Lai Y.-L.;Chen C.-Y.;Chung-Yi Hu;Tien H.-F.;Ou D.-L.;Lin L.-I.; Lu J.-W.; Lin Y.-M.; Lai Y.-L.; Chen C.-Y.; CHUNG-YI HU; Tien H.-F.; Ou D.-L.; Lin L.-I. |
| 臺大學術典藏 |
2021-03-15T07:59:41Z |
Cytarabine-resistant FLT3-ITD leukemia cells are associated with TP53 mutation and multiple pathway alterations—possible therapeutic efficacy of cabozantinib
|
Ko Y.-C.;Chung-Yi Hu;Liu Z.-H.;Tien H.-F.;Ou D.-L.;Chien H.-F.;Lin L.-I.; Ko Y.-C.; CHUNG-YI HU; Liu Z.-H.; Tien H.-F.; Ou D.-L.; Chien H.-F.; Lin L.-I. |
| 臺大學術典藏 |
2021-03-15T07:59:41Z |
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)
|
Lu J.-W.;Wang A.-N.;Liao H.-A.;Chen C.-Y.;Hou H.-A.;Chung-Yi Hu;Tien H.-F.;Ou D.-L.;Lin L.-I.; Lu J.-W.; Wang A.-N.; Liao H.-A.; Chen C.-Y.; Hou H.-A.; CHUNG-YI HU; Tien H.-F.; Ou D.-L.; Lin L.-I. |
| 臺大學術典藏 |
2021-03-09T05:18:38Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Ying-Chun Shen; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:35Z |
Induction of DNA damage-inducible gene GADD45�] contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Ou D.-L.; Ying-Chun Shen; Yu S.-L.; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:32Z |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Ying-Chun Shen; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T08:01:17Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Shen Y.-C.; JA-DER LIANG; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-05T06:29:41Z |
CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia
|
Lin T.-C.;Hou H.-A.;Wen-Chien Chou;Ou D.-L.;Yu S.-L.;Tien H.-F.;Lin L.-I.; Lin T.-C.; Hou H.-A.; WEN-CHIEN CHOU; Ou D.-L.; Yu S.-L.; Tien H.-F.; Lin L.-I. |
| 臺大學術典藏 |
2021-02-02T02:47:55Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; PING-NING HSU; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-04T12:12:28Z |
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)
|
Wang A.-N.; Lu J.-W.; Lin L.-I.; Ou D.-L.; HWEI-FANG TIEN; Hu C.-Y.; Hou H.-A.; Liao H.-A.; Chen C.-Y. |
| 臺大學術典藏 |
2020-06-17T03:01:53Z |
Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Ou D.-L.;Shen Y.-C.;Sung-Liang Yu;Chen K.-F.;Yeh P.-Y.;Fan H.-H.;Feng W.-C.;Wang C.-T.;Lin L.-I.;Hsu C.;Cheng A.-L.; Ou D.-L.; Shen Y.-C.; SUNG-LIANG YU; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-06-17T03:01:52Z |
CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia
|
Lin T.-C. ;Hou H.-A. ;Chou W.-C. ;Ou D.-L. ;Sung-Liang Yu ;Tien H.-F. ;Lin L.-I.; Lin T.-C.; Hou H.-A.; Chou W.-C.; Ou D.-L.; SUNG-LIANG YU; Tien H.-F.; Lin L.-I. |
| 臺大學術典藏 |
2020-06-16T07:53:41Z |
Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy
|
Ou D.-L.;Chen C.-L.;Lin S.B.;Hsu C.-H.;Liang-In Lin; Ou D.-L.; Chen C.-L.; Lin S.B.; Hsu C.-H.; LIANG-IN LIN |
| 臺大學術典藏 |
2020-06-16T07:53:37Z |
CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia
|
Lin T.-C.;Hou H.-A.;Chou W.-C.;Ou D.-L.;Yu S.-L.;Tien H.-F.;Liang-In Lin; Lin T.-C.; Hou H.-A.; Chou W.-C.; Ou D.-L.; Yu S.-L.; Tien H.-F.; LIANG-IN LIN |
| 臺大學術典藏 |
2020-06-16T07:53:23Z |
Cytarabine-resistant FLT3-ITD leukemia cells are associated with TP53 mutation and multiple pathway alterations—possible therapeutic efficacy of cabozantinib
|
Ko Y.-C.;Hu C.-Y.;Liu Z.-H.;Tien H.-F.;Ou D.-L.;Chien H.-F.;Liang-In Lin; Ko Y.-C.; Hu C.-Y.; Liu Z.-H.; Tien H.-F.; Ou D.-L.; Chien H.-F.; LIANG-IN LIN |
| 臺大學術典藏 |
2020-05-25T06:52:04Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Cheng A.-L.;Hsu C;Yen-Shen Lu;Wang D.-S;Fan H.-H;Yu S.-L;Liou J.-Y;Liang J.-D;Shen Y.-C;Ou D.-L; Ou D.-L; Shen Y.-C; Liang J.-D; Liou J.-Y; Yu S.-L; Fan H.-H; Wang D.-S; YEN-SHEN LU; Hsu C; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:00Z |
I�eB kinases increase Myc protein stability and enhance progression of breast cancer cells
|
Yeh P.-Y;Yen-Shen Lu;Ou D.-L;Cheng A.-L.; Yeh P.-Y; YEN-SHEN LU; Ou D.-L; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:13Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:17Z |
Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Shen Y.-C.; Ou D.-L.; Ou D.-L.;Shen Y.-C.;Yu S.-L.;Chen K.-F.;Yeh P.-Y.;Fan H.-H.;Feng W.-C.;Wang C.-T.;Lin L.-I.;Chiun Hsu;Cheng A.-L.; Cheng A.-L.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Chiun Hsu; Chen K.-F.; Yu S.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Comparative microRNA detection from precursor-microRNA-transfected hepatocellular carcinoma cells by capillary electrophoresis with dual-color laser-induced fluorescence
|
Ou D.-L.; Chiun Hsu; Huang S.-H.; Chang P.-L.; Yang T.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:12Z |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Shen Y.-C.; Ou D.-L.; Chiun Hsu; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
|
Ou D.-L.; Lee B.-S.; Chang Y.-C.; Lin L.-I.; Liou J.-Y.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:09Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:08Z |
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin
|
Ou D.-L.;Lee B.-S.;Lin L.-I.;Liou J.-Y.;Liao S.-C.;Chiun Hsu;Cheng A.-L.; Ou D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Ou D.-L.;Shyue S.-K.;Lin L.-I.;Feng Z.-R.;Liou J.-Y.;Fan H.-H.;Lee B.-S.;Chiun Hsu;Cheng A.-L.Ann-Lii; Ou D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; Chiun Hsu; Cheng A.-L.Ann-Lii |
| 臺大學術典藏 |
2020-04-10T12:51:06Z |
H3K9 histone methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis
|
Wu P.-C.; Lu J.-W.; Yang J.-Y.; Lin I.-H.; Ou D.-L.; Lin Y.-H.; Chou K.-H.; Huang W.-F.; Wang W.-P.; Huang Y.-L.; Chiun Hsu; Lin L.-I.; Lin Y.-M.; James Shen C.-K.; Tzeng T.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Chiun Hsu; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:02Z |
Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy
|
Chang P.-L.; Lin W.-Y.; Chiun Hsu; Chang H.-Y.; Ou D.-L.; Lin Y.-Z.; Lin Y.-Z.;Ou D.-L.;Chang H.-Y.;Lin W.-Y.;Chiun Hsu;Chang P.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y.;Tan C.-T.;Chen C.-W.;Ou D.-L.;Cheng A.-L.;Chiun Hsu; Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:00Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.;Lin Y.-Y.;Hsu C.-L.;Lin Y.-Y.;Chen C.-W.;Yu J.-S.;Miaw S.-C.;Hsu P.-N.;Cheng A.-L.;Chiun Hsu; Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; YU-YUN SHAO; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-03-07T06:56:33Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Lin Y.-L.; Liau J.-Y.; Yu S.-C.; Ou D.-L.; Lin L.-I.; Tseng L.-H.; YIH-LEONG CHANG; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-06T08:25:06Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.;Chang C.-J.;Yung-Ming Jeng;Lin Y.-J.;Lin Z.-Z.;Gandhi A.K.;Liao S.-C.;Huang Z.-M.;Hsu C.;Cheng A.-L.; Ou D.-L.; Chang C.-J.; YUNG-MING JENG; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T12:22:25Z |
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
|
Liau J.-Y.; SHAN-CHI YU; Ou D.-L.; Lin L.-I.; Tseng L.-H.; Chang Y.-L.; Yeh K.-H.; Cheng A.-L.; Lin Y.-L. |
